Activation of insulin-like growth factor II signaling by mutant type p53: Physiological implications for potentiation of IGF-II signaling by p53 mutant 249

Molecular and Cellular Endocrinology

Volumn 203, Issue 1-2, 2003, Pages 51-63

  Lee, Young Ik ^a   Han, Yoo Jung ^a   Lee, Soo Young ^a   Lee, Yoon Ik ^a   Park, Sook Kyung ^a   Park, Youn Jung ^a   Moon, Hyung Bae ^b   Shin, Jeh Hoon ^c   Lee, Je Ho ^d  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Wonkwang University   (South Korea)

^c Hanyang University College of Medicine   (South Korea)

^d Samsung Medical Center   (South Korea)

Author keywords

Aflatoxin B1; AS ODS; Hepatocellular carcinoma; IGF II M6P R; IGF IR; IRS 1; P53mt249; RT PCR; Tyrosine phosphorylation; IR3

Indexed keywords

MEVINOLIN; MUTANT PROTEIN; PROTEIN P53; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; BINDING SITE; CARCINOGENESIS; CELL GROWTH; CODON; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PARACRINE SIGNALING; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0038361085     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(03)00117-5     Document Type: Article

References (36)

1. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth. Cancer Res. 55:1995;249-252.
2. Baserga R., Hongo A., Rubini M., Prisco M., Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta. 1332:1997;F105-F126.
3. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 350:1991;429-431.
4. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B.I., Seizinger B.R., Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 377:1995;646-649.
5. Carlberg M., Dricu A., Blegan H., Wang M.O., Hjertman M., Zickert P., Hoong A., Larsson O. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J. Biol. Chem. 271:1996;17 453-17 462.
6. Cariani E., Lasserre C., Seurin D., Hamelin B., Kemeny F., Franco D., Czech M.P., Ullrich A., Brechot C. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 48:1988;6844-6849.
7. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
8. Cooke D.W., Bankert L.A., Roberts C.T. Jr., LeRoith D., Casella S.J. Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem. Biophys. Res. Commun. 177:1991;1113-1120.
9. Girnita L., Girnita A., Brodin B. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 60:2000;5278-5283.
10. Hartshorn M.A., Scott C.D., Baxter R.C. Immunofluorescent localization of type II insulin-like growth factor receptor in rat liver and hepatoma cells. J. Endocr. 121:1988;221-227.
11. Hongo A., Yumet G., Resnicoff M., Romano G., O'Connor R., Baserga R. Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristylated COOH terminus of the insulin-like growth factor I receptor. Cancer Res. 58:1998;2477-2484.
12. Hsiao M., Low J., Dorn E. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 145:1994;702-714.
13. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:1991;427-428.
14. Iwamoto K.S., Mizuno T., Ito T., Tsnyama N., Kyoizumi S., Seyanma T. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res. 56:1996;3862-3865.
15. Kern S.E., Pietenpol J.A., Thiagalingam S., Seymour A., Kinzler K.W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 256:1992;827-830.
16. Kim S.O., Park J.G., Lee Y.I. Increased expression of the IGF-I receptor gene in HCC: implications of IGF-IR gene activation by HBV-X. Cancer Res. 56:1996;3831-3836.
17. Kozma L.M., Weber M.J. Constitutive phosphorylation of the receptor for insulin like growth factor I in cells transformed by the src oncogene. Mol. Cell Biol. 10:1990;3626-3634.
18. Kull F.C., Jacobs S., Su Y.F., Svoboda M.E., Van Wyk J.J., Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin-c. J. Biol. Chem. 258:1983;6561-6566.
19. Lanyi A., Deb D., Seymour R.C., Ludes-Meyers J.H., Subler M.A., Deb S. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene. 16:1998;3169-3176.
20. Lee Y.I., Lee S., Lee Y.I., Hyun S.W., Yoo Y.D., Kim S.J., Kim Y.W., Poo H.R. The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter. Oncogene. 16:1998;2367-2380.
21. Lee Y.I., Lee S., Das G.C., Lee Y.I. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implication for a gain of-function during the formation of hepatocellular carcinoma. Oncogene. 19:2000;3717-3776.
22. Luse D.S., Roeder R.G. Accurate transcription initiation on a purified mouse beta-globin DNA fragment in a cell-free system. Cell. 20:1980;691-699.
23. Narayan S., Roy D. Insulin-like growth factor 1 receptors are increased in estrogen-induced kidney tumors. Cancer Res. 53:1993;2256-2259.
24. O'Connor R., Kauffmann-Zen A., Liu Y., Lehar S., Evan G.I., Baserga R., Blattler W.A. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell Biol. 17:1997;427-435.
25. Ohlsson C., Kley N., Werner H., LeRoith D. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinol. 139:1998;1101-1107.
26. Oda T., Tsuda H., Scarpa A., Sakamoto M., Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 52:1992;6358-6464.
27. Osborne C.K., Coronado E.B., Kitten L.J., Arteaga C.I., Fuqua S.A. Insulin-like growth factor for human breast cancer acting via the IGF-I receptor. Mol. Endocrinol. 3:1989;1701-1709.
28. Prisco M., Hongo A., Rizzo M.G., Sacchi A., Baserga R. The insulin-like growth factor 1 receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol. Cell Biol. 17:1997;1084-1092.
29. Resnicoff M., Baserga R. The role of the insulin-like growth factor I receptor in transformation and apoptosis. Ann. N.Y. Acad. Sci. 842:1998;76-81.
30. Rubini M., Hongo A., D'Ambrosio C., Baserga R. Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-1 (IGF-I) receptor gene. Exp. Cell Res. 230:1997;284-292.
31. Scatchard G. Monoclonal antibodies to receptors for insulin and somatomedin-C. Ann. N.Y. Acad. Sci. 51:1949;660-672.
32. Stweart A.J., Johnson M.D., May F.E., Westley B.R. Role of insulin-like growth factors and type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 265:1990;21 172-21 178.
33. Werner H., Karnieli E., Rauscher F.J., LeRoith D. Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor 1 receptor gene. Proc. Natl. Acad. Sci. USA. 93:1996;8318-8323.
34. Werner H., Bach M.A., Stannard B., Roberts C.T. Jr., LeRoith D. Structural and functional analysis of the insulin-like growth factor I receptor gene promoter. Mol. Endocrinol. 6:1992;1545-1558.
35. Yang D., Faris R., Hixson D., Affigne S., Rogler C.E. Insulin-like growth factor II blocks apoptosis of N-myc2 expressing woodchuck liver epithelial cells. J. Virol. 70:1996;6260-6268.
36. Zhang L., Kashanchi F., Zhan Q., Zhan S., Brady J.N. Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res. 56:1996;1367-1373.